for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

Frequent urination often signals underlying health conditions that require medical attention. While occasional increases in ...

There is a wide range of variability with how often one should pee, particularly in regard to what’s “normal.” Learn if you ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), today announced the first patient has been randomized and dosed in a Phase 2 clinical study evaluating sunobinop ...

Bladder training is a behavioral treatment that may be effective in eliminating bedwetting (or enuresis) among children. Bladder training seeks to increase the capacity of the bladder and the strength ...

A recent groundbreaking study revealed that an amnion/chorion (AC) bilayer product could treat interstitial cystitis/bladder ...

Oct. 9, 2024 — A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. Types of cancers found to have a small increased ...

Key Takeaways Men’s incontinence is a common issue affecting many individuals globally. Understanding the types and causes ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...